Benjamin Hohl, CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 6,018 shares at $58.35 ($353K) on 2026-08-17, disclosed to the SEC on 2026-08-19.
Scheduled sale ($353k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $58.35 | 4,630 | $270K | 76.6% |
| 2 | $59.35 | 1,388 | $82K | 23.4% |
| Total | $58.58 avg | 6,018 | $353K | 100% |
| Filing → |
| ELVN | SELL | 2026-06-22 | $264K | — | Filing → |
| ELVN | SELL | 2026-03-10 | $296K | — | Filing → |
| ELVN | SELL | 2025-10-01 | $66K | — | Filing → |